Adverse Event Monitoring for Biosimilars: How Safety Surveillance Works in 2026
Biosimilars aren't like generics - they need special safety tracking. Learn how adverse event monitoring works in 2026, why naming and traceability matter, and what patients and providers can do to improve safety.
